Capricor Therapeutics and CureDuchenne to Host Webinar on

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Capricor Therapeutics and CureDuchenne to Host Webinar on November 3, 2015 at 3:00 p.m. ET

LOS ANGELES, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq: CAPR ), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics and CureDuchenne , a national nonprofit organization dedicated to finding a cure for Duchenne muscular dystrophy, invite participants to join a webinar “HOPE-Duchenne: A Clinical Trial for Individuals with Heart Disease Related to DMD” on Tuesday, November 3, 2015 at 3:00 p.m. ET/noon PT.

Speakers include:

  • John Jefferies, MD, Study Principal Investigator, Cincinnati Children’s Hospital Medical Center
  • Linda Marbán, PhD, CEO, Capricor, Inc.
  • Brian Fedor, Study Manager, Capricor, Inc.
  • Debra Miller, Founder and Chief Executive Officer of CureDuchenne
  • Dr. Michael Kelly, PhD, Chief Scientific Advisor for CureDuchenne

Capricor is testing an investigational cardiac cell therapy to determine if reducing the amount of scar tissue in the heart can lead to better outcomes in Duchenne muscular dystrophy.  The HOPE-Duchenne trial will evaluate if an investigational cardiac cell therapy is safe and potentially effective in treating boys and young men with Duchenne.  The HOPE-Duchenne trial will study the amount of scar tissue in the heart muscle before and after treatment with either the investigational cardiac cell therapy or usual care.  The webinar will provide an overview of the clinical trial which is being conducted at several sites in the U.S.  To find a site, see the list on www.ClinicalTrials.gov (Study Identifier NCT02485938).  

The HOPE-Duchenne trial will evaluate CAP-1002 for the first time in patients with Duchenne with significant cardiac dysfunction. CAP-1002 is Capricor's allogeneic, cardiosphere-derived cell (CDC) therapy already in clinical development for the treatment of heart disease. CureDuchenne Ventures invested in Capricor to support the development of its clinical program for Duchenne. Heart failure is the leading cause of death in patients with Duchenne.

To join the webinar please call (844-337-8088) and enter conference ID number 71482322. Visit here: https://cc.readytalk.com/cc/s/registrations/n...pn7mtweznr to register online.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR ) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics. Our lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. The Company has two leading product candidates under investigation: CAP-1002, a cardiac cell therapy; and Cenderitide, a natriuretic peptide receptor agonist. CAP-1002 is in development for the treatment of post myocardial infarction (heart attack), advanced heart failure and Duchenne muscular dystrophy associated cardiomyopathy. Cenderitide is in development for the outpatient treatment of heart failure as well as potential other indications. In addition, the Company is conducting research and development on its exosomes platform technology for cardiac diseases and other potential indications. For additional information visit www.capricor.com .

About CureDuchenne Ventures and CureDuchenne

CureDuchenne Ventures LLC collaborates with pharmaceutical and biotechnology companies to facilitate the development of drugs to treat Duchenne muscular dystrophy. CureDuchenne Ventures LLC was formed by CureDuchenne, a national nonprofit that has a successful track record of supporting research and raising awareness of the disease.

CureDuchenne was founded in 2003 with a focus on saving the lives of those with Duchenne muscular dystrophy, a disease that affects more than 300,000 boys worldwide.  With support from CureDuchenne, three pharmaceutical treatments could be approved by the FDA within the next year.  These treatments may lessen the effects of the disease for those with certain mutations of Duchenne, but there is still much to be done to find a cure.  For more information, please visit CureDuchenne.org and follow us on Facebook , Twitter and YouTube .

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; scope, duration, validity and enforceability of intellectual property rights; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; future royalty streams, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact our business are set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission on March 16, 2015, in our Registration Statement on Form S-3, as filed with the Securities and Exchange Commission on September 25, 2015, and in our Quarterly Report on Form 10-Q for the period ending June 30, 2015, as filed with the Securities and Exchange Commission on August 14, 2015. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements.

For more information, please contact: Capricor Therapeutics, Inc. AJ Bergmann, Vice President of Finance +1-310-358-3200 abergmann@capricor.com CureDuchenne Karen Harley, Vice President of Marketing and Communication 949-872-2552 karen@cureduchenne.org

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 17

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
AIC Hotel Group's 11 Awards Test Resort Market Reach

Updated Category News Views 89

Eleven Trophies, Four Properties, One Useful Signal Hospitality awards can be a lot of polished brass and very little cash flow, but this batch is substantial enough to deserve a hard look. AIC Hotel Group collected 11 honors spanning Condé Nast Traveler's 2026 Readers' Choice Awards, Travel Weekly's 2026 Magellan Awards, and Good Housekeeping's 2027 Travel Awards. The...

Continue Reading
Saban Center Partnership Gives Health Learning a Lift

Updated Category News Views 45

A dinosaur race may sound like pure kid bait, but the underlying idea is sturdier than that. Cardiac Solutions and the Seale family are backing an interactive health-and-performance exhibit at Tuscaloosa’s planned Saban Center, a project intended to turn questions about movement, fitness, heart rate and oxygen levels into something children can actually touch, test and...

Continue Reading
RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 138

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
FLX Opens a New Door to Pre-IPO Deal Flow for Advisors

Updated Category News Views 126

Private-market chatter has been leaking past the velvet rope for years, and advisors are sick of learning about it after a client already has a pitch deck in hand. FLX Networks is responding to that irritation by letting its eligible advisor and wealth-management members review select pre-IPO opportunities shared by other members. Announced November 19, 2026, the move is...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 164

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Intel Investors Face January 12 Lead Plaintiff Deadline

Updated Category News Views 110

A Narrow Calendar Window Has Opened Intel holders have another legal deadline to put on the fridge, and this one is not a casual housekeeping item. A securities class action has been filed in the Northern District of California on behalf of investors who bought or acquired Intel shares between July 23, 2026, and October 29, 2026. The deadline to seek appointment as lead...

Continue Reading
CMA Wins Spotlight Greenberg Traurig’s Music Bench

Updated Category News Views 81

Four trophies on one awards night can say plenty about the machinery behind a music career, even if nobody should confuse a CMA acceptance speech with a balance-sheet event. Greenberg Traurig’s entertainment practice is celebrating client wins at the 60th annual CMA Awards, held Nov. 18, 2026: three honors tied to Miranda Lambert and one for Brooks & Dunn. For investors...

Continue Reading
Caregiver Strategy Puts a Hard Truth on the Table Today

Updated Category News Views 47

Sixty-three million people carrying care responsibilities is not a side issue; it is a national load-bearing wall. The 2026 National Strategy to Support Family Caregivers arrives with that reality plainly in view, and frankly, it is overdue for the country to treat family care as core infrastructure rather than a private household problem somebody is expected to absorb...

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 118

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading

Top 5 Most Recently Viewed Articles

Eastman Chemical’s Stock Surge Marks a Turning Point for Investors

Updated Category News Views 82

Eastman Chemical's Stock Hits New Heights Eastman Chemical Company (NYSE: EMN) has recently reached an impressive milestone, with its stock price climbing to a 52-week high of $107.14. This significant price point reflects growing investor confidence and a positive market outlook for the company. With a remarkable 34.6% increase over the past year, Eastman Chemical has...

Continue Reading
BOS Expands Automation Solutions with New System Orders

Updated Category News Views 270

BOS Secures New Orders for Robotic Solutions BOS Better Online Solutions Ltd. (NASDAQ: BOSC), renowned for its expertise in supply chain technologies, has recently announced a significant milestone. The company secured orders for two innovative robotic packing and palletizing systems aimed at enhancing efficiency in food manufacturing. Details of the New Orders These new...

Continue Reading
Amazon's Cloud and AI Strategy Set to Shape Future Growth

Updated Category News Views 260

Overview Amazon.com, Inc. (NASDAQ: AMZN) plays a crucial role in the realms of e-commerce, cloud computing, digital streaming, and artificial intelligence. Recent analyses from respected financial institutions provide a thorough insight into Amazon's market performance, strategic initiatives, and its future outlook. This article brings together these evaluations, zeroing...

Continue Reading
WTW's Strategic Acquisitions: A Leap into the Future of Insurance

Updated Category News Views 211

WTW Expands Through Innovative Acquisitions Willis Towers Watson Public Ltd., known as WTW, is making headlines with its ambitious strategy to enhance its technology-enabled insurance and workplace benefits services. By announcing two consequential acquisitions, WTW aims to broaden its reach in the middle market while modernizing its client interactions significantly....

Continue Reading
Genmab's Share Buy-Back Program: Recent Transaction Details

Updated Category News Views 173

Introduction to Genmab Genmab A/S is a pioneering biotechnology company based in Copenhagen, Denmark, dedicated to improving the lives of patients through innovative antibody therapies. Founded in 1999, Genmab has continuously worked on developing groundbreaking antibody technology platforms, aiming to advance treatment for serious diseases such as cancer. Share Buy-Back...

Continue Reading